Navigation Links
ThromboGenics N.V.: Business Update
Date:11/6/2008

pected to begin in Q1 2009. It is anticipated that this Phase III development program will use the 125 (micro)g dose of microplasmin.

The decision to move into this Phase III program was in part based on the positive results from the Phase IIb MIVI III trial announced in late June. The MIVI III (MIVI III - Microplasmin for Vitreous Injection) trial showed that the most effective dose of microplasmin studied (125 (micro)g) was able to resolve the underlying disease in approximately 30% of patients without the need for a vitrectomy (surgical intervention). The encouraging results from this study were presented by Dr. George Williams (Beaumont Hospital, Michigan, USA) on June 28 at the World Ophthalmology Congress in Hong Kong.

The MIVI III trial was a Phase IIb, randomized, double-masked, placebo-controlled, dose-ranging trial that evaluated three doses of microplasmin (25, 75 and 125 (micro)g) versus placebo in 125 patients scheduled for vitrectomy. The patients were recruited at 19 centers across the United States. The trial was designed to assess the safety and efficacy of microplasmin intravitreal injection given 7 days prior to the patient's planned vitrectomy.

The study showed that microplasmin was well tolerated. The trial also showed a clear dose response curve with the highest dose (125 (micro)g) of microplasmin delivering the best results. In this group, 10 of the 32 patients receiving this dose of microplasmin had resolution of their underlying disease, and therefore did not need a vitrectomy for the indication for which they were being treated. This compares very favorably with the placebo group, where only 1 patient out of 31 achieved the same positive outcome. In addition, use of microplasmin was associated with a reduced amount and duration of suction needed to achieve a PVD in patients who progressed to surgical intervention, compared to placebo.

The visual acuity of all patients recruited into the study was also measured at
'/>"/>

SOURCE ThromboGenics NV
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. ThromboGenics Announces Half Year Results 2008
2. ThromboGenics Appoints Dr. Patrik De Haes as Chief Executive Officer
3. ThromboGenics Announces Private Investors Acquire 8% Stake in the Company
4. ThromboGenics and BioInvent Announce a Strategic Alliance With Roche for TB-403, a Novel Anti-Cancer Antibody
5. ThromboGenics N.V. - Business Update
6. ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke
7. ThromboGenics Announces 2007 Full Year Results
8. ThromboGenics and BioInvent Receive Approval to Begin Clinical Trials of TB-403 for the Treatment of Cancer
9. ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting
10. ThromboGenics Presents Results of the Vitreomacular Traction Trial (MIVI IIT) at the American Society of Retina Specialists Annual Meeting
11. ThromboGenics and BioInvent Announce Publication of Exciting Data on a Novel Class of Angiogenesis Inhibitors in Cell
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... September 19, 2014 Follow ... potential to revolutionize the world has attracted diverse ... and small start-ups. The early years of nanotechnology ... largely due to the high risks involved, which ... earmarked for this evolving technology have been growing ...
(Date:9/19/2014)... BioTech News Coverage: Progress made ... of studies and trials.  Companies in focus are: GenSpera ... LLY ), Gilead Sciences Inc. (NASDAQ: ... and Arena Pharmaceuticals Inc. (NASDAQ: ARNA) GenSpera, ... for the treatment of cancer, announced that the United ...
(Date:9/19/2014)... , September 19, 2014 The ... Spain , available today on PharmaBoardroom.com ... the Eurozone crisis that rocked the Spanish economy in 2009, ... Spanish pharma community has remained pragmatic in times of trouble. ... is still the fifth biggest European market, and the general ...
(Date:9/18/2014)... 2014 A novel robotic system that ... is currently being tested as part of a biomedical ... Boston with the aim of determining if the robot, ... cancer biopsies faster, more accurate, less costly, and less ... the potential to deliver prostate cancer therapies with greater ...
Breaking Biology Technology:Growing R&D Investments & Developments in Nanomaterials to Drive the Global Nanotechnology Market, According to New Report by Global Industry Analysts, Inc. 2Growing R&D Investments & Developments in Nanomaterials to Drive the Global Nanotechnology Market, According to New Report by Global Industry Analysts, Inc. 3Growing R&D Investments & Developments in Nanomaterials to Drive the Global Nanotechnology Market, According to New Report by Global Industry Analysts, Inc. 4Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 2Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 3Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 4Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 5Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 6Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 7PharmaBoardroom Releases New Spain Pharmaceuticals Report 2PharmaBoardroom Releases New Spain Pharmaceuticals Report 3Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 2Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 3Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 4Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 5Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 6
... BioStorage Technologies, Inc.,(BST), announces the appointment of ... European operations in Griesheim, Germany. Hoffer,joins BST with ... fields of,clinical pharmacology and toxicology. In his new ... Chief Operating Officer for BST, and will,manage all ...
... Managed Care ... Facilities, ... ), a leading developer of,biosensor and microprocessor technologies for use in ... professional pulse oximeters; the PulseOx 6000(TM) and PulseOx,6100(TM)., At the ...
... declares spirit of hope and focus on mission, ... today,named Northwestern Medical Faculty Foundation as its expected ... proton therapy cancer treatment,and research center to be ... miles west of Chicago., The announcement came ...
Cached Biology Technology:BioStorage Technologies Appoints Dr. Wolfgang Hoffer as Managing Director of European Operations 2SPO Medical Begins Shipping PulseOx 6000(TM) and PulseOx 6100(TM) 2SPO Medical Begins Shipping PulseOx 6000(TM) and PulseOx 6100(TM) 3NIU Seeks OK for New Proton Cancer Treatment and Research Center 2NIU Seeks OK for New Proton Cancer Treatment and Research Center 3
(Date:9/18/2014)... -- Arizona turned its newborn screening program into a model ... earning it the first-ever Newborn Screening Quality Award from the ... Will Humble, M.P.H., Arizona,s Department of Health Services director, with ... established a policy of full transparency for the length of ... to the lab for analysis, and set a target of ...
(Date:9/18/2014)... from several disciplines will be celebrated tonight at the ... in improving the health of premature infants and in ... The researchers, whose work was supported by the National ... former Atomic Energy Commission, will be honored at a ... A bipartisan group of Members of Congress will be ...
(Date:9/18/2014)... Elsevier, a world-leading provider of scientific, technical and ... Research Management Society (ARMS), recognized the academic research ... Scopus Young Researcher of the Year Awards. , ... National Convention Centre and in conjunction with the ... representing Australia,s and New Zealand,s scientific community. Guest ...
Breaking Biology News(10 mins):March of Dimes honors Arizona with first-ever newborn screening award 2March of Dimes honors Arizona with first-ever newborn screening award 33rd annual Golden Goose award ceremony honors 8 researchers; Unusual work had big results 2Elsevier and Australasian Research Management Society award scientists at Scopus ceremony 2
... and thrust," humans try to bank money to obtain financial ... gains. Many humans also end up in poverty traps, where ... living they find themselves unable to raise their heads above ... period, Gregory Rasmussen, currently at Lady Margaret Hall Oxford, intensively ...
... 1980s when they stumbled on small sugar molecules lurking in ... to be there, but they certainly weren,t supposed to be ... on and off. The conventional wisdom was that the ... determining their actions -- fell to phosphates, in a ...
... Laboratories engineer, and Bruce Osborn, chief operating officer of ... Mechanics magazine Breakthrough Innovator Award Oct. 15 during a ... Sponsored by Bristol-Myers Squibb, the Breakthrough Awards celebrate ... behind them. The joint Sandia/SES award is among 21 ...
Cached Biology News:Running on rocket fuel 2Johns Hopkins researchers detect sweet cacophony while listening to cellular cross-talk 2Sandia, SES win Popular Mechanics Breakthrough Innovator Award 2